| Bioactivity | SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas[1]. |
| CAS | 2661481-41-8 |
| Formula | C18H12ClF4N9O |
| Molar Mass | 481.79 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Adam Olszewski MD, et al. A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies.Blood. Volume 142, Supplement 1, 2 November 2023, Page 3102. |
SGR-1505
CAS: 2661481-41-8 F: C18H12ClF4N9O W: 481.79
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proli
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.